(PDF) Phase IV, Open-Label, Safety Study Evaluating the Use

Phase IV, Open-Label, Safety Study Evaluating the Use of Dexmedetomidine in Pediatric Patients Undergoing Procedure-Type Sedation

Frontiers in Pharmacology - Switzerland

doi 10.3389/fphar.2017.00529

Full Text

Abstract

Available in full text

Categories

Date

August 11, 2017

Authors

Edmund H. Jooste

Gregory B. Hammer

Christian R. Reyes

Vaibhav Katkade

Publisher

Frontiers Media SA

Related search

Open-Label Phase I Clinical Study to Assess the Safety and Efficacy of Cilostazol in Patients Undergoing Internal Carotid Artery Stent Placement

Interventional Neurology

Cardiovascular Medicine

English

Pharmacokinetics and Safety of Apremilast in Pediatric Patients With Moderate to Severe Plaque Psoriasis: Results From a Phase 2 Open-Label Study

Journal of the American Academy of Dermatology

English

Update on Dexmedetomidine: Use in Nonintubated Patients Requiring Sedation for Surgical Procedures

Therapeutics and Clinical Risk Management

English

A Phase I-Ii, Open-Label, Multicenter Trial to Determine the Dosimetry and Safety of 99mTc-Sestamibi in Pediatric Subjects

Journal of Nuclear Medicine

Nuclear Medicine

English

Dexmedetomidine/Propofol Versus Dexmedetomidine/Ketamine Versus Dexmedetomidine as a Sole Agent for Pediatric Sedation During MRI

Ain-Shams Journal of Anesthesiology

English

Safety and Efficacy of Procedural Sedation and Analgesia in Pediatric Oncology Patients

English

Evaluating Dose Regimens of Apomorphine, an Open-Label Study

International Journal of Impotence Research

English

Is Dexmedetomidine the Gold Standard for Pediatric Procedural Sedation and Anxiolysis?

Revista da Associacao Medica Brasileira

English

Results of a Phase I, Open-Label, Randomized, Crossover Study Evaluating the Effects of Linifanib on QTc Intervals in Patients With Solid Tumors

Cancer Chemotherapy and Pharmacology

Cancer Research

English